×

Polymorphisms in the PDE3A gene

  • US 9,512,481 B2
  • Filed: 09/13/2010
  • Issued: 12/06/2016
  • Est. Priority Date: 09/11/2009
  • Status: Active Grant
First Claim
Patent Images

1. A method for treating a human patient with heart failure comprising treating the patient with an effective amount of a PDE3A inhibitor after the patient is determined to be homozygous for an insertion of an ectotropic viral integration site-1 (Evi-1) binding site in the phosphodiesterase type 3A (PDE3A) gene promoter, wherein the Evi-1 binding site insertion is 85% identical to SEQ ID NO:

  • 2 and is located within 2000 nucleotides 5′

    of the PDE3A gene transcriptional initiation site and wherein the PDE3A inhibitor is amrinone, cilostazol, milrinone, quazinone, siguazodan, trequinsin, or enoximone.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×